Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aldosterone blockade in cardiovascular disease.

× No keyword cloud information.

19 in total

Review 1. The clinical implications of endothelial dysfunction.

Authors: Michael E Widlansky; Noyan Gokce; John F Keaney; Joseph A Vita
Journal: J Am Coll Cardiol Date: 2003-10-01 Impact factor: 24.094

2. Mineralocorticoid receptor antagonism in experimental atherosclerosis.

Authors: Sanjay Rajagopalan; Damon Duquaine; Steven King; Bertram Pitt; Paresh Patel
Journal: Circulation Date: 2002-05-07 Impact factor: 29.690

3. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Authors: C A Farquharson; A D Struthers
Journal: Circulation Date: 2000-02-15 Impact factor: 29.690

4. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245

5. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors: B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal: N Engl J Med Date: 1999-09-02 Impact factor: 91.245

6. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Authors: Mariantonietta Cicoira; Luisa Zanolla; Lorenzo Franceschini; Andrea Rossi; Giorgio Golia; Prisca Zeni; Beatrice Caruso; Piero Zardini
Journal: Am J Cardiol Date: 2002-02-15 Impact factor: 2.778

7. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

Authors: Myron H Weinberger; Barbara Roniker; Scott L Krause; Robert J Weiss
Journal: Am J Hypertens Date: 2002-08 Impact factor: 2.689

8. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Authors: Bertram Pitt; Nathaniel Reichek; Roland Willenbrock; Faiez Zannad; Robert A Phillips; Barbara Roniker; Jay Kleiman; Scott Krause; Daniel Burns; Gordon H Williams
Journal: Circulation Date: 2003-09-29 Impact factor: 29.690

9. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy.

Authors: Colin A J Farquharson; Allan D Struthers
Journal: Clin Sci (Lond) Date: 2002-10 Impact factor: 6.124

10. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.

Authors: Henry Krum; Hector Nolly; Diane Workman; Weizhong He; Barbara Roniker; Scott Krause; Kaffa Fakouhi
Journal: Hypertension Date: 2002-08 Impact factor: 10.190

10 in total

1. Aldosterone antagonists in the treatment and prevention of heart failure.

Authors: Rebecca S Boxer; Mark E Dunlap
Journal: Curr Treat Options Cardiovasc Med Date: 2005-12

Review 2. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?

Authors: Kathleen M Knights; Arduino A Mangoni; John O Miners
Journal: Br J Clin Pharmacol Date: 2006-06 Impact factor: 4.335

3. An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease.

Authors: James B Wetmore; Kirsten L Johansen; Saunak Sen; Adriana M Hung; David H Lovett
Journal: Hum Genet Date: 2006-06-22 Impact factor: 4.132

Review 4. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.

Authors: Anil Verma; Scott D Solomon
Journal: Curr Heart Fail Rep Date: 2007-12

Review 5. Mineralocorticoid receptor antagonists and endothelial function.

Authors: Bradley A Maron; Jane A Leopold
Journal: Curr Opin Investig Drugs Date: 2008-09

Review 6. Obesity-related glomerulopathy and podocyte injury: a mini review.

Authors: Marcello Camici; Fabio Galetta; Nader Abraham; Angelo Carpi
Journal: Front Biosci (Elite Ed) Date: 2012-01-01

7. Non-steroidal anti-inflammatory drug (NSAID) related inhibition of aldosterone glucuronidation and arterial dysfunction in patients with rheumatoid arthritis: a cross-sectional clinical study.

Authors: Michael A Crilly; Arduino A Mangoni
Journal: BMJ Open Date: 2011-05-20 Impact factor: 2.692

8. Differential Sympathetic Vasomotor Activation Induced by Liver Cirrhosis in Rats.

Authors: Heder F G Estrela; Elaine S Damásio; Eduardo K U N Fonseca; Cássia T Bergamaschi; Ruy R Campos
Journal: PLoS One Date: 2016-04-07 Impact factor: 3.240

9. Identification of Mineralocorticoid Receptors, Aldosterone, and Its Processing Enzyme CYP11B2 on Parasympathetic and Sympathetic Neurons in Rat Intracardiac Ganglia.

Authors: Lukas Dehe; Shaaban A Mousa; Noureddin Aboryag; Mohammed Shaqura; Antje Beyer; Michael Schäfer; Sascha Treskatsch
Journal: Front Neuroanat Date: 2022-01-11 Impact factor: 3.856

10. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population.

Authors: Romance Nguetse Djoumessi; Jean Jacques N Noubiap; Francois Folefack Kaze; Mickael Essouma; Alain Patrick Menanga; Andre Pascal Kengne; Jean Claude Mbanya; Eugene Sobngwi
Journal: BMC Res Notes Date: 2016-03-23

10 in total